Undersøgelse for at udforske den terapeutiske effekt af Eluxadoline til behandling af irritabel tyktarm med diarré hos børn
Fase 2, randomiseret, dobbeltblind, placebokontrolleret, parallelgruppe, dosisvarierende undersøgelse til evaluering af sikkerheden og effektiviteten af eluxadoline hos pædiatriske deltagere (alder 6 til 17 år) med irritabel tyktarm med diarré (IBS-D)
The primary objectives of this study are to explore the therapeutic effect of eluxadoline in treating irritable bowel syndrome with diarrhea (IBS-D) in pediatric participants 6-17 years of age, to evaluate the pharmacokinetics of eluxadoline in pediatric participants with IBS-D, and to evaluate the safety and tolerability of eluxadoline in pediatric participants with IBS-D. Enrollment of 12-17 years old age group is closed, enrollment of the 6-11 years old age group will continue.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
-
Kozloduy, Bulgarien, 3320
- MHATSv.Ivan Rilski /ID# 235399
-
Plovdiv, Bulgarien, 4001
- University Hospital Plovdiv /ID# 235450
-
-
Gabrovo
-
Sevlievo, Gabrovo, Bulgarien, 5400
- Medical center 1 Sevlievo /ID# 237473
-
-
-
-
-
Edmonton, Canada, T6G 1C9
- Duplicate_Edmonton Clinic Health Academy (ECHA) /ID# 234917
-
Winnepeg, Canada, R3E 3P4
- Manitoba Institute of Child Health /ID# 235448
-
-
-
-
-
Blackpool, Det Forenede Kongerige, FY3 8NR
- Blackpool Teaching Hospitals NHS Foundation Trust /ID# 237273
-
-
Greater London
-
London, Greater London, Det Forenede Kongerige, SE5 9RS
- Kings College Hospital NHS Foundation Trust /ID# 236305
-
-
Lancashire
-
Manchester, Lancashire, Det Forenede Kongerige, M13 9WL
- Duplicate_Manchester University NHS Foundation Trust /ID# 234663
-
-
-
-
Arkansas
-
Hot Springs, Arkansas, Forenede Stater, 71913
- HealthStar Research of Hot Springs PLLC /ID# 234609
-
Little Rock, Arkansas, Forenede Stater, 72212-4187
- Applied Research Center of Arkansas /ID# 238070
-
-
California
-
Corona, California, Forenede Stater, 92879
- Kindred Medical Institute, LLC /ID# 237368
-
Garden Grove, California, Forenede Stater, 92845
- Duplicate_VVCRD Research /ID# 234606
-
Paramount, California, Forenede Stater, 90723
- Duplicate_Center for Clinical Trials LLC /ID# 234630
-
-
Florida
-
Miami, Florida, Forenede Stater, 33130
- Sunrise Research Institute /ID# 237382
-
Miami, Florida, Forenede Stater, 33155
- South Miami Medical & Research Group Inc. /ID# 234655
-
Miami, Florida, Forenede Stater, 33165
- Valencia Medical & Research Center /ID# 234672
-
Miami, Florida, Forenede Stater, 33174
- Florida Research Center, Inc. /ID# 236514
-
Miami Lakes, Florida, Forenede Stater, 33016
- Duplicate_Wellness Clinical Research /ID# 237401
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30315
- Global Research Associates /ID# 234646
-
Atlanta, Georgia, Forenede Stater, 30342
- Children's Ctr Digestive, US /ID# 237575
-
Stockbridge, Georgia, Forenede Stater, 30281
- Sleep Care Research Institute d/b/a Clinical Research Institute /ID# 236343
-
-
Illinois
-
Park Ridge, Illinois, Forenede Stater, 60068
- Advocate Children's Hospital-Park Ridge /ID# 235388
-
-
Indiana
-
Indianapolis, Indiana, Forenede Stater, 46202
- Indiana University Health Riley Hospital for Children /ID# 235400
-
-
Kentucky
-
Lexington, Kentucky, Forenede Stater, 40517
- Michael W. Simon, MD, PSC /ID# 236517
-
-
Maryland
-
New Market, Maryland, Forenede Stater, 21774-6154
- Frederick County Pediatrics /ID# 234519
-
-
Minnesota
-
Minneapolis, Minnesota, Forenede Stater, 55413-2195
- MNGI Digestive Health, P. A. /ID# 238057
-
-
New Jersey
-
Marlton, New Jersey, Forenede Stater, 08053
- Celen Medical Group Corp - Marlton /ID# 234922
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Forenede Stater, 73106
- IPS Research Company /ID# 237672
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forenede Stater, 19104-4319
- Children's Hospital of Philadelphia - Main /ID# 234313
-
Pittsburgh, Pennsylvania, Forenede Stater, 15236
- Preferred Primary Care Physicians, Inc. /ID# 236436
-
-
Texas
-
Fort Worth, Texas, Forenede Stater, 76104
- Cook Children's Med. Center /ID# 237537
-
Houston, Texas, Forenede Stater, 77030-2608
- Texas Children's Hospital /ID# 238304
-
San Antonio, Texas, Forenede Stater, 78215
- Sun Research Institute /ID# 236933
-
-
West Virginia
-
Morgantown, West Virginia, Forenede Stater, 26506
- West Virginia University Hospitals /ID# 256841
-
-
-
-
North Holland
-
Amsterdam, North Holland, Holland, 1105 AZ
- Duplicate_Academisch Medisch Centrum /ID# 237117
-
-
-
-
Lesser Poland Voivodeship
-
Krakow, Lesser Poland Voivodeship, Polen, 30-539
- Specjalistyczne Gabinety Sp. z o.o. /ID# 236347
-
-
Masovian Voivodeship
-
Warsaw, Masovian Voivodeship, Polen, 00-189
- Centrum Zdrowia MDM /ID# 237269
-
Warsaw, Masovian Voivodeship, Polen, 04-730
- Duplicate_Instytut Pomnik - Centrum Zdrowia Dziecka /ID# 234311
-
-
Podkarpackie Voivodeship
-
Rzeszów, Podkarpackie Voivodeship, Polen, 35-302
- Korczowski Bartosz Gabinet Lekarski /ID# 234683
-
-
Pomeranian Voivodeship
-
Gdansk, Pomeranian Voivodeship, Polen, 80-803
- Copertnicus Podmiot Leczniczy Sp. z o.o. /ID# 235656
-
-
Łódź Voivodeship
-
Lodz, Łódź Voivodeship, Polen, 93-338
- Instytut Centrum Zdrowia Matki Polki /ID# 237438
-
-
-
-
-
Valencia, Spanien, 46017
- Hospital Universitario Dr. Peset /ID# 236755
-
-
-
-
-
Wuppertal, Tyskland, 42283
- HELIOS Klinikum Wuppertal /ID# 237322
-
-
-
-
-
Budapest, Ungarn, 1125
- Eszak-Kozep-budai Centrum, Uj Szent Janos Korhaz /ID# 236993
-
Sopron, Ungarn, 9400
- Soproni Erzsebet Oktato Korhaz es Rehabilitacios Intezet /ID# 237341
-
Székesfehérvár, Ungarn, 8000
- Vita Verum Medical Bt. /ID# 234321
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
-
Participant must provide written or verbal informed assent and the parent/guardian/LAR must provide written informed consent before the initiation of any study-specific procedures.
-
Participant is a male or female outpatient, 6 to 17 years of age inclusive, at the time the participant provides assent for the study and parent/guardian/LAR has provided signed consent.
-
Participant is able to read and understand the assessments in the eDiary. If the participant is 6 to 11 years of age and does not meet this criterion, the interviewer-administered version of the eDiary must be used and the parent/guardian/LAR or caregiver who will be administering the interviewer-administered version of the eDiary must be able to read and understand the assessments in the eDiary and must undergo training.
-
Female participants must not be pregnant, breastfeeding, or considering becoming pregnant during the study or for approximately 30 days after the last dose of study drug. Female participants of childbearing potential must have a negative serum pregnancy test at Visit 1 (screening) and a negative urine pregnancy test at Visit 3 (randomization) prior to dosing.
-
Female participants of childbearing potential must practice at least 1 protocol-specified method of birth control, that is effective from Study Day 1 through at least 30 days after the last dose of study drug. Local practices may require 2 methods of birth control. Female participants of non-childbearing potential do not need to use birth control.
-
Participant has a diagnosis of IBS-D as defined by the modified Rome IV child/adolescent criteria: Must include all of the following:
-- Abdominal pain at least 4 days per month over at least 2 months associated with one or more of the following:
-
Related to defecation
-
A change in frequency of stool
-
A change in form (appearance) of stool
- After appropriate evaluation, the symptoms cannot be fully explained by another medical condition.
- Participant has predominantly diarrheal stool symptoms defined as Bristol stool types 6 or 7 for more than 25% of bowel movements and Bristol stool types 1 or 2 for less than 25% of bowel movements that occur in the absence of laxative.
-
Participant may be newly diagnosed with IBS-D by the investigator at Visit 1. All criteria for diagnosis must be fulfilled for at least 2 months prior to Visit 1 (screening).
-
-
Participant has been compliant with the eDiary by completing both the morning and evening assessments for at least 8 out of the 14 days immediately preceding Visit 3 (randomization).
-
Participant has an average daytime abdominal pain score greater than or equal to 1.0 over the 2 weeks prior to randomization.
-
Participant has at least 1 daytime bowel movement with a consistency of Type 6 or Type 7 on the pediatric Bristol Stool Form Scale (p-BSFS) on at least 2 days per week during the 2 weeks immediately prior to randomization and that occurs in the absence of laxatives.
Exclusion Criteria:
-
Participant has no gallbladder, (ie, agenesis of the gallbladder or cholecystectomy).
-
Participant has had any of the following surgeries:
- Any abdominal surgery within the 3 months prior to Screening; or
- A history of major gastric, hepatic, pancreatic, or intestinal surgery. (Note: appendectomy, hemorrhoidectomy, or polypectomy greater than 3 months post-surgery are allowed. For the purposes of this study, laparoscopic surgeries without complication are considered minor and non-exclusionary, provided the condition for which the surgery was performed was not exclusionary.)
-
Participant has a history of chronic or severe constipation or sequelae from constipation, or known or suspected mechanical GI obstruction or pseudo obstruction.
-
Participant has a history or current diagnosis of constipation with encopresis.
-
Participant meets the child/adolescent Rome IV criteria of IBS with constipation, IBS with constipation and diarrhea (mixed), unspecified IBS, or functional constipation.
-
Participant has a history of intestinal obstruction, stricture, toxic megacolon, GI perforation, fecal impaction, gastric banding, bariatric surgery, adhesions, ischemic colitis, or impaired intestinal circulation.
-
Participant has a documented history of hepatic impairment as defined by Child-Pugh Classification Grade A, B or C.
-
Participant has a history or current diagnosis of inflammatory or immune-mediated lower GI disorders including inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis, microscopic colitis). Crohn's disease affecting the upper GI tract would also be exclusionary.
-
Participant has celiac disease, or a positive serological test for celiac disease and the condition has not been ruled out by endoscopic biopsy.
-
Participant has any congenital and/or acquired malabsorption syndrome (eg, Shwachman-Diamond syndrome).
-
Participant has a history of a microbiologically documented (ie, stool culture or medical history) GI infection within 3 months prior to Screening.
-
Participant has a known lactose or fructose intolerance that is associated with diarrhea, abdominal pain or discomfort, and that could confound assessments in the study.
-
Participant has a history of diverticulitis within 3 months prior to Screening.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Tredobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Eluxadoline 25mg
Eluxadoline 25mg, oral administration, twice daily |
Oral tablets
Andre navne:
|
|
Eksperimentel: Eluxadoline 50mg
Eluxadoline 50mg, oral administration, twice daily |
Oral tablets
Andre navne:
|
|
Eksperimentel: Eluxadoline 100mg
Eluxadoline 100mg, oral administration, twice daily |
Oral tablets
Andre navne:
|
|
Eksperimentel: Placebo
Dose-matched placebo, oral administration, twice daily |
Oral tablets |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change from baseline in stool consistency averaged over the 4-week Treatment Period
Tidsramme: Baseline (2 Weeks prior to randomization) to Week 4
|
Stool consistency will be assessed using the Pediatric Bristol Stool Form Scale (p-BSFS) on a range from 1 (Hard Lumps) to 7 (Watery). |
Baseline (2 Weeks prior to randomization) to Week 4
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change from baseline in stool consistency for daily daytime and nighttime stool consistency scores
Tidsramme: Baseline (2 Weeks prior to randomization) to Week 4
|
Stool consistency will be assessed using the Pediatric Bristol Stool Form Scale (p-BSFS) on a range from 1 (Hard Lumps) to 7 (Watery). |
Baseline (2 Weeks prior to randomization) to Week 4
|
|
Change from baseline for daytime, nighttime, and 24-hour abdominal pain scores
Tidsramme: Baseline (2 Weeks prior to randomization) to Week 4
|
Abdominal Pain is scored on a five-point ordinal scale, with 0 meaning no pain, and 4 meaning a lot of pain. |
Baseline (2 Weeks prior to randomization) to Week 4
|
|
Change from baseline for daytime, nighttime, and 24-hour bowel movement frequency
Tidsramme: Baseline (2 Weeks prior to randomization) to Week 4
|
Change from baseline in the number of bowel movements. |
Baseline (2 Weeks prior to randomization) to Week 4
|
|
Change from baseline for daytime, nighttime, and 24 hour urgency-free days
Tidsramme: Baseline (2 Weeks prior to randomization) to Week 4
|
Change from baseline in the number of urgency free days in a week. |
Baseline (2 Weeks prior to randomization) to Week 4
|
|
Change from baseline for daytime, nighttime, and 24 hour number of fecal incontinence-free days
Tidsramme: Baseline (2 Weeks prior to randomization) to Week 4
|
Change from baseline in the number of fecal incontinence-free days in a week. |
Baseline (2 Weeks prior to randomization) to Week 4
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Studieleder: ABBVIE INC., AbbVie
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 3030-202-002
- 2017 (U.S. NIH-bevilling/kontrakt)
- 2017-003770-14 (EudraCT nummer)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
IPD-delingstidsramme
For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
IPD-delingsadgangskriterier
To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- SAP
- CSR
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .